Findings from the randomized, phase 3 ADMIRAL study have found the FLT3 inhibitor gilteritinib (Xospata, Astellas) doubles the likelihood of complete remission in patients with relapsed or refractory FLT3-mutated acute myeloid leukemia (AML), compared with that seen with salvage chemotherapy (N Engl J Med 2019;381[18]:1728-1740).
“Treatment options for patients with relapsed or refractory FLT3-mutated AML are largely limited to various salvage chemotherapy regimens, and there is no